Drug Profile
Calcitonin intranasal - Unigene
Alternative Names: Fortical Intranasal; Nasal calcitonin - Unigene; Recombinant salmon calcitonin intranasal; Salcatonin intranasal - Unigene; sCT nasalLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Unigene Laboratories
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin receptor agonists; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Postmenopausal osteoporosis
Most Recent Events
- 11 Mar 2013 The US FDA Advisory Committe concludes that the benefits of calcitonin products do not outweigh the risks, and should not continue to be broadly marketed
- 07 Jun 2011 Unigene terminates its involvement in Unigene Biotechnology (the China Joint Venture) and recovers all intellectual property rights granted under the agreement with Shijiazhuang Pharmaceutical Group
- 03 Apr 2008 Phase-III clinical trials in Postmenopausal osteoporosis (Intranasal)